RxDoctor Payments Data

Krishna Priya Raju, MD

Pulmonary Disease · Fort Myers, FLNPI 1922058940

Payments from drug & device makers

$972in general payments, 2019–2025

Across 54 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$245
  • AstraZeneca$159
  • Boehringer Ingelheim$127
  • Resmed Corp$67
  • Baxter Healthcare$54
  • United Therapeutics Corporation$48
  • plus $272 from 9 others

What the payments were for

  • Food & beverage$95498%
  • Education$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$972 in reported general payments places this provider in the 25th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$149,466
Medicare patients
616
Services billed
1,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter315$286,325
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr208$147,786
Breztri AerosphereBudesonide/Glycopyr/Formoterol85$72,525
Spiriva RespimatTiotropium Bromide87$62,136
TezspireTezepelumab-Ekko13$53,683
Stiolto RespimatTiotropium Br/Olodaterol Hcl84$52,952
Breo ElliptaFluticasone/Vilanterol72$36,918
SymbicortBudesonide/Formoterol Fumarate100$30,661
Incruse ElliptaUmeclidinium Bromide30$16,342
Advair HfaFluticasone Propion/Salmeterol24$10,018
Pirfenidone11$9,261
BreynaBudesonide/Formoterol Fumarate41$8,804
Albuterol Sulfate HfaAlbuterol Sulfate306$8,542
Levalbuterol Tartrate HfaLevalbuterol Tartrate71$4,413
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$3,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$245$489,555636 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort$159$156,868198 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$127$115,088171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →